Art

J-GLOBAL ID：201402288047347594   Reference number：14A1484060

Present Profiles of Novel Anticoagulant Use in Japanese Patients with Atrial Fibrillation: Insights from the Rivaroxaban Postmarketing Surveillance Registry

心房細動の日本人患者における新規抗凝固薬使用の現代プロファイル リバロキサバン市販後調査レジストリからの洞察

Author (11)： OGAWA Satoshi (International Univ. of Health and Welfare Mita Hospital, Tokyo, JPN) ,  IKEDA Takanori (Dep. of Cardiovascular Medicine, Toho Univ. Medical Center, Tokyo, JPN) ,  KITAZONO Takanari (Dep. of Medicine and Clinical Sci., Graduate School of Medical Sciences, Kyushu Univ., Fukuoka, JPN) ,  NAKAGAWARA Jyoji (Integrative Stroke Imaging Center, National Cerebral and Cardiovascular Center, Suita, Osaka, JPN) ,  MINEMATSU Kazuo (National Cerebral and Cardiovascular Center Hospital, Suita, Osaka, JPN) ,  MIYAMOTO Susumu (Dep. of Neurosurgery, Kyoto Univ., Kyoto, JPN) ,  MURAKAWA Yuji (The Fourth Dep. of Internal Medicine, Teikyo Univ. School of Medicine, Mizonokuchi Hospital, Kawasaki, JPN) ,  IEKUSHI Kazuma (Dep. of Medical Affairs, Bayer Yakuhin, Ltd, Osaka, JPN) ,  YAMANAKA Satoshi (Dep. of Medical Affairs, Bayer Yakuhin, Ltd, Osaka, JPN) ,  YAMADA Takashi (Dep. of Medical Affairs, Bayer Yakuhin, Ltd, Osaka, JPN) ,  INUYAMA Lyo (Dep. of Medical Affairs, Bayer Yakuhin, Ltd, Osaka, JPN)
Material： Journal of Stroke & Cerebrovascular Diseases  (J Stroke Cerebrovasc Dis)
Volume： 23  Issue： 10  Page： 2520-2526  Publication year： Nov. 2014 
JST Material Number： W1420A  ISSN： 1052-3057  Document type： Article
Article type： 原著論文  Country of issue： United States (USA)  Language： ENGLISH (EN)

Thesaurus term： *anticoagulant ,...
Semi thesaurus term： Oral anticoagulant ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A1484060&from=J-GLOBAL&jstjournalNo=W1420A") }}

JST classification (2)： Clinical application of drugs acting on blood and body fluid  (GW14020X) ,  Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M)

Substance index (1)： Rivaroxaban

Reference (9)：

• European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
• Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-2765.
• Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880.
• Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost 2005;3:514-521.

Terms in the title (9)： 心房細動 ,  日本人 ,  患者 ,  抗凝固薬 ,  プロファイル ,  リバロキサバン ,  市販後調査 ,  レジストリ ,  洞察